(Street)

DALLAS

(City)

TX

(State)

1. Name and Address of Reporting Person*

TOI HC I, LLC

75201

(Zip)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB Number: 32:
Estimated average burden

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

	tions may conti ction 1(b).	nue. <i>See</i>		Filed	d pursua or Se	ant to	Sec 30(ction 16(a)	of the s	Securi	ities Exchang	e Act o f 1940	f 1934			hou	rs per re	esponse:	0.5
		f Reporting Person* Ithcare Partne		<u>.P.</u>				e and Tick							elationship ck all app Direc	,	ting Pe	. ,	Issuer Owner
(Last) (First) (Middle) 2100 MCKINNEY AVE, SUITE 1760					3. Date of Earliest Transaction (Month/Day/Year) 09/07/2022								Office below	er (give titl v)	е	Othe below	r (specify v)		
(Street) DALLAS TX 75201			4. If <i>i</i>	Amen	idme	ent, Date o	of Origin	riginal Filed (Month/Day			y/Year)		6. Individual or Joint/Group Filing (Check / Line) Form filed by One Reporting Pers X Form filed by More than One Rep						
(City)	(St		Zip)																
1. Title of	Security (Ins		1 - No	2. Transacti Date (Month/Day	ion	2A. E Exec if any	Deer cutio	1	3. Transa Code (8)	ction	4. Securities Disposed Of 5)	Acquir	ed (A)	or	5. Amou Securitie Benefici Owned I	int of es ally Following	Form	nership Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) or (D)	Pric	е	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)
Common	stock			09/07/2	022				S		45,000	D	\$6.	04(1)	15,17	72,729		I	See footnote(
Common stock 09				09/08/2	09/08/2022				S		23,500	D	\$6.	04(2)	15,149,229		I		See footnote(4
Common stock			09/09/2022				S		18,900	D	\$5	.8(3)	15,130,329				See footnote(
		Та	ble II								osed of, convertib				Owne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transa Code 8)	action			_	Exer	cisable and	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		8. D S. (I	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	e O s Fe ally D o g (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Benefic Owners ct (Instr. 4
					Code	v	(,	A) (D)	Date Exerci	sable	Expiration Date	Title	Amou or Numb of Share	er					
		f Reporting Person* Ithcare Partne		. <u>P.</u>															
(Last) 2100 MC		(First) AVE, SUITE 17		liddle)															
(Street) DALLA	S	TX	75	5201															
(City)		(State)	(Z	ip)															
		f Reporting Person [*] Ithcare Partne		P, LLC															
(Last) 2100 MC		(First) AVE, SUITE 17		liddle)															

(Last) 2100 MCKINN	(Middle) 1760		
(Street) DALLAS	TX	75201	
(City)	(State)	(Zip)	

Explanation of Responses:

- 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$5.62 to \$6.18, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$5.77 to \$6.17, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$5.70 to \$5.96, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- 4. TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

Remarks:

/s/ Havencrest Healthcare
Partners, L.P., by Kyle Seco,
as attorney-in-fact
/s/ Havencrest Healthcare
Partners GP, LLC, by Kyle
Seco, as attorney-in-fact
/s/ TOI HC I, LLC, by Kyle
Seco, as attorney-in-fact
** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.